Avid Bioservices Inc (CDMO)

[BioBS2012]

" Using multiple tumor models in mice, we demonstrate PS targeting antibodies enhance the anti-tumor activity of multiple forms of therapy including anti-CTLA-4 and anti-PD-1 checkpoint inhibitor antibodies."

Dia, when you look at the above quote and also the title of the presentation, it certainly looks like this will be the first disclosure of the PD-1 data with BAVI.

GTC Novel Immunotherapeutics Summit 2014- Jan 30
Speaker: Bruce Freimark, PhD, Phosphatidylserine Targeting Antibodies Enhances Activity of Immune Checkpoint Inhibitors and Re-activates Immune System in Tumors

Should be interesting in deed. I would even venture to say that we will see the data release via a PR prior to the presentation - maybe even next week? For sure during the week of January 27th. !!